Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Zimmer BioMet

Zimmer Biomet Stock: Is ZBH Underperforming the Healthcare Sector?

Zimmer Biomet has underperformed the healthcare sector over the past year, yet analysts remain moderately bullish about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Despite Zimmer Biomet underperforming the broader market over the past year, analysts remain moderately bullish on the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Zimmer Biomet’s Report

Zimmer Biomet will release its second-quarter earnings next month, and analysts anticipate a single-digit profit growth.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Ministers cannot be the last to know when inward investors like Zimmer Biomet pull out of Wales

A more constructive approach to managing relationships with major employers is important in the future especially if they are in receipt of public funding.

Birmingham Post

Deep concern as Zimmer Biomet closure in Bridgend puts 540 jobs at risk

The announcement has left a community in shock

Wales Online

Hundreds of jobs at threat at South Wales hip replacement factory

Zimmer Biomet has confirmed plans to close its factory in Bridgend

Birmingham Post

540 jobs at risk as Bridgend Zimmer Biomet plant set to close

Zimmer Biomet in Bridgend has entered into consultation with its staff

Wales Online

Read news from The Economist, FT, and more,
with one subscription

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo Corporation (NASDAQ: MASI) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%.

Benzinga

SVB Leerink Maintains Outperform Rating for Zimmer Biomet Holdings: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Zimmer Biomet Holdings (NYSE:ZBH) and raise its price target from $135.00 to $140.00. Shares of Zimmer Biomet Holdings are trading up 0.82% over the last 24 hours, at $121.67 per share.

Benzinga

Zimmer Biomet Raises, Tightens FY22 Outlook after Q1 Earnings Surpass Estimates

Zimmer Biomet Holdings Inc's (NYSE:ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis), beating the consensus of $1.59 billion. Adjusted EPS was $1.61, which came in above the consensus of $1.41 and $1.55 a year ago. "We are encouraged by the better than expected results…

Benzinga

1 2

Organisations

Bridgend County Borough Council

Zimmer Biomet Holdings

16 stories

Zimmer

12 stories

Zimmer Biomet Holdings Inc

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Covid-19

31,413 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.